Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05499013 · ClinicalTrials.gov registry record · Phase 1
Study to Assess SLN124 in Patients With Polycythemia Vera
A Phase 1 study of Polycythemia Vera, sponsored by Silence Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
- 20
- Study locations
NCT05499013: Active Phase 1 study of Polycythemia Vera, sponsored by Silence Therapeutics.
NCT05499013 is a Phase 1 study of Polycythemia Vera that is active but no longer recruiting, run by Silence Therapeutics. The registered enrollment target is 69 participants, below the 337-participant average among 22 other Polycythemia Vera trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05499013, a Phase 1 study of Polycythemia Vera, is active but no longer recruiting, sponsored by Silence Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 1/2, multicenter study with an open-label dose escalation followed by a randomized placebo controlled and double-blind phase of SLN124 in adult patients with Polycythemia Vera (PV) to assess the safety, tolerability, efficacy, pharmacokinetic (PK), and Pharmacodynamic (PD) response of SLN124.
Primary Outcome
Safety and tolerability will be reported separately following open-label dose escalation phase and double-blind phase
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SLN124
Study Locations (20)
Other
- Research Site - Benowa
- Research Site - Hobart
- Research Site - Kurralta Park
- Research Site 2 - Melbourne
- Research Site - Melbourne
- Linear Clinical Research - Nedlands
- Research Site - Richmond
- Research Site 2 - Plovdiv
- Research Site - Plovdiv
- Research Site - Toronto
- Research Site - Freiburg im Breisgau
- Research Site - Hanover
- Research Site - Alessandria
- Research Site - Meldola
- Research Site - Johor Bahru
New York
- Research Site - Buffalo
- Research Site - New York
Louisiana
- Research Site - Hammond
Ohio
- Research Site - Columbus
Texas
- Research Site - Huntsville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2023-01-26 |
| Est. Completion | 2030-03 |
| Phase | Phase 1 |
What the registry record for NCT05499013 still lists
NCT05499013 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 69 participants, a relatively small participant target, below the 337-participant average among 22 other Polycythemia Vera trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Polycythemia Vera appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05499013 names 20 study sites across 5 states, led by Other, New York, Louisiana.
Frequently Asked Questions
What is clinical trial NCT05499013 about?
NCT05499013 is a clinical study titled "Study to Assess SLN124 in Patients With Polycythemia Vera". This is a Phase 1/2, multicenter study with an open-label dose escalation followed by a randomized placebo controlled and double-blind phase of SLN124 in adult patients with Polycythemia Vera (PV) to assess the safety, tolerability, efficacy, pharmacokinetic (PK), and Pharmacodynamic (PD) response o...
What is the current status of trial NCT05499013?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2023-01-26. Estimated completion is 2030-03.
What conditions does trial NCT05499013 study?
This clinical trial studies the following conditions: Polycythemia Vera.
What interventions are being tested in trial NCT05499013?
The interventions under investigation include: Placebo (DRUG), SLN124 (DRUG).
Who is sponsoring clinical trial NCT05499013?
This trial is sponsored by Silence Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05499013 being conducted?
This trial has 20 study locations across Louisiana, New York, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Polycythemia Vera
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05499013's enrollment target sits among peer trials
69 9th of 22 higher than 14 of 22 other Polycythemia Vera trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Polycythemia Vera trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
RECRUITING · Phase 1
-
An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
RECRUITING · Phase 1
-
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
COMPLETED · Phase 1
-
TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea
COMPLETED · Phase 1
-
Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
COMPLETED · Phase 1
-
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04020575 · 69 participants · Phase 1
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
- NCT04163614 · 69 participants · NA
Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients
- NCT04164641 · 69 participants · NA
Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic Gait Correction in Reducing Diabetic Foot Ulceration Or Subsequent Amputation in Patients With a History of a Diabetic Foot Ulceration
- NCT04493372 · 69 participants · NA
Deciphering Preserved Autonomic Function After Spinal Cord Injury
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI